Shukra Pharmaceuticals Ltd Q2FY26 | From Gandhinagar to the Globe: 341% Profit Surge, Army Orders, and a ₹24 Cr Afghan Export Contract – Small Cap Turns Big Drama

1. At a Glance

Shukra Pharmaceuticals Ltd, the Gandhinagar-based pharma upstart that once made basic tablets, is suddenly punching like a heavyweight. With a market cap of ₹1,790 crore, this WHO-GMP certified firm now flaunts a 341% quarterly profit jump, a 5.8 crore quarterly sales, and a 2.38 crore PAT in Q2FY26. That’s right — a once side-lined stock that traded at ₹5 not long ago now sits proudly at ₹40.9 per share, after delivering a 601% one-year return. ROE? A juicy 15.9%, and ROCE? A more-than-decent 21.8%.

What makes it spicier? The company just bagged a ₹24 crore Afghan supply order, clinched a PAN-India distribution tie-up with Wockhardt for ESIC/Defence, floated warrants worth ₹15.78 crore, and — wait for it — set up a new robotics subsidiary. From penicillin tablets to AI robots, Shukra is doing everything short of launching a space capsule.

But here’s the real masala: despite trading at a P/E of 150, it’s almost debt-free (Debt: ₹3.76 crore). So, is this the birth of a microcap miracle or just a perfectly marketed multivitamin bubble? Let’s open the blister pack.

2. Introduction – From Rakanpur to Razzmatazz

Incorporated in 1993, Shukra Pharmaceuticals spent decades as a quiet contract manufacturer, producing humble pills for bigger pharma bosses. Fast-forward to FY25-26, and it’s now suddenly on investor watchlists for all the right reasons — orders, expansions, and right issues flying faster than paracetamol in flu season.

Its 10-acre Gandhinagar facility isn’t just a plant anymore; it’s a launchpad. The company’s rise from ₹5 to ₹40 is the kind of story that makes smallcap Telegram groups lose sleep.

Over the past five years, Shukra has grown profits at a 244% CAGR, while ROE and ROCE have clocked consistently above 20%. It’s managed this without heavy leverage, thanks to prudent cost control and a growing export base — Australia, Kenya, Sri Lanka, Vietnam, and Uganda among them.

The cherry on top? In November 2025, Shukra launched Shukra Robotics Pvt Ltd, holding an 85% stake — because clearly, after tablets and tonics, robots are the next logical step. From pharma to AI, this company’s to-do list looks like a college student’s new year resolutions — ambitious, slightly random, but definitely bold.

3. Business Model – WTF Do They Even Do?

Shukra’s core game remains manufacturing and marketing pharmaceutical formulations. Think tablets, capsules, and small-volume parenterals — the bread and butter of every generic pharma player. But there’s more under the hood.

They operate under two major divisions:

1. Pharma Manufacturing & Trading – The company manufactures antibiotics (Penicillin, Cephalosporins, Macrolides, Quinolones, etc.), antifungals, antivirals, antidepressants, and more. Basically, if there’s a disease, Shukra has a chemical friend for it.
2. Laboratory Testing Services – They don’t just make pills, they also test them — a nice way to double-dip on the same drug lifecycle.

The FY23 revenue breakup says it all:

• Sale of Product: 21%
• Trading: 58%
• Sale of Services: 4%
• Commission Income: 17%

Yup, trading still rules their topline, but the high-margin manufacturing and export arms are clearly taking off.

The company is even launching a new wellness division — Shukra Wellness — focusing on Mouth Dissolving Strips (MDS) for Rx and nutraceutical products. Translation: they’re chasing the fancy “wellness” money.

Oh, and about that global reach — Shukra now exports to over 12 countries across Africa, Asia, and Europe. Gandhinagar is suddenly shipping antibiotics to Peru and Guatemala. Who knew Gujarat could cure the world’s infections one strip at a time?

4. Financials Overview – The Quarter That Roared

EBITDA may look moody, but PAT’s explosion suggests strong other income (₹1.71 crore this quarter). This makes the earnings quality questionable — not shady, but definitely spiced up with non-operating income.

Still, a 341% PAT growth is nothing to sneeze at. The company managed to hold margins despite erratic OPM swings — the pharma equivalent of surviving a roller coaster without losing your lunch.

5. Valuation Discussion – The Fair Value Thali

Let’s chew through the numbers.

• Current EPS (Q2FY26): ₹0.05 → Annualised EPS = ₹0.20
• CMP: ₹40.9 → P/E = 204x (vs. Industry 31x)

That’s like buying a generic paracetamol at Gucci prices.

EV/EBITDA Calculation:
EV = ₹1,781 Cr
EBITDA (TTM) = ₹12 Cr
→ EV/EBITDA = 148x

For context, Divi’s trades at ~30x EV/EBITDA.

Using even optimistic assumptions:

• Fair Value by